Teva Pharmaceutical Industries (NYSE:TEVA) Given New $42.00 Price Target at Bank of America

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective hoisted by Bank of America from $38.00 to $42.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s target price indicates a potential upside of 36.66% from the stock’s current price.

Several other brokerages have also recently weighed in on TEVA. Barclays boosted their price objective on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. Piper Sandler reissued an “overweight” rating and set a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Finally, Scotiabank boosted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $38.78.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock traded up $0.21 during trading hours on Thursday, hitting $30.73. The stock had a trading volume of 1,429,918 shares, compared to its average volume of 8,655,933. Teva Pharmaceutical Industries has a one year low of $12.47 and a one year high of $37.35. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. The stock’s 50-day moving average price is $31.99 and its two-hundred day moving average price is $28.02. The stock has a market capitalization of $35.34 billion, a price-to-earnings ratio of 25.61, a PEG ratio of 10.13 and a beta of 0.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the firm posted $0.71 earnings per share. The business’s revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities analysts forecast that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 62,102 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the transaction, the insider directly owned 224,940 shares in the company, valued at $6,779,691.60. This trade represents a 21.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Richard Daniell sold 17,295 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $547,732.65. Following the transaction, the executive vice president owned 85,755 shares in the company, valued at $2,715,860.85. The trade was a 16.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 920,901 shares of company stock valued at $30,056,789. Insiders own 0.49% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Phoenix Financial Ltd. increased its position in shares of Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after acquiring an additional 3,533,800 shares during the period. National Pension Service increased its position in shares of Teva Pharmaceutical Industries by 24.2% in the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock valued at $41,881,000 after acquiring an additional 404,526 shares during the period. Public Sector Pension Investment Board increased its position in shares of Teva Pharmaceutical Industries by 11.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock valued at $13,543,000 after acquiring an additional 69,000 shares during the period. Oak Harvest Investment Services acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $1,010,000. Finally, Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Teva Pharmaceutical Industries by 12.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after acquiring an additional 4,306,363 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.